跳至主要内容
临床试验/NCT03344146
NCT03344146已完成不适用

Electronic Monitoring and Improvement of Adherence to Direct Oral Anticoagulant Treatment - a Randomised Crossover Study of an Educational and Reminder-based Intervention in Ischaemic Stroke Patients Under Polypharmacy

University Hospital, Basel, Switzerland1 个研究点 分布在 1 个国家目标入组 130 人开始时间: 2017年12月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
130
试验地点
1
主要终点
Change of non-optimal timing adherence to DOACs

研究概览

简要总结

Primary objective of the MAAESTRO trial is to evaluate the impact of an educational and reminder-based intervention on the adherence of stroke patients to DOACs. Secondary objectives are to evaluate the association between non-adherence and clinical events, to identify predictors of non-adherence and to compare objective measures of adherence with self-reporting.

Key methodological instrument for this study will be the "Time4Med" pillbox with Smart/ Reminder Card. The study includes 3 visits (baseline visit 0, follow-up visit 1 and end-of-study visit 2) with a total follow-up of 9 months.

After an initial 3-month observational phase with electronic monitoring of adherence using the "Smart Card", all patients will receive counselling based on their electronically recorded drug intake data, as well as a multicompartment pillbox. Patients will be then randomised to one of two groups in a crossover design, so that in the subsequent 6-month interventional phase one group will use a (reminder-delivering) "Reminder Card" for the first 3 months and the "Smart Card" for the last 3 months, while the second group will use the cards in reverse order.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Health Services Research
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Signed informed consent form (ICF)
  • •Adult patients (≥ 18 years)
  • •Hospitalization for acute ischaemic stroke (including TIA with positive neuroimaging)
  • •DOAC treatment for atrial fibrillation or embolic stroke of undetermined source
  • •Patients receiving polypharmacy, defined as at least 3 drugs (including DOAC treatment)
  • •Patients self-administering their medication
  • •Patients already using a pillbox or willing to use one

排除标准

  • •Patients not able or unwilling to sign ICF
  • •Medication administration by caregiver - Filling of the pillbox by a pharmacy, relatives or other caregivers does not exclude the patients, provided that they self-administer their medication
  • •Patients who are, in the opinion of the investigator, unlikely to adhere to the study schedule or are unsuitable for any other reason

研究组 & 干预措施

Group 1

Other

Intake reminders followed by crossover to no intake reminders

干预措施: Medication intake reminders (Behavioral)

Group 1

Other

Intake reminders followed by crossover to no intake reminders

干预措施: Pillbox use and counselling (Behavioral)

Group 2

Other

No intake reminders followed by crossover to intake reminders

干预措施: Medication intake reminders (Behavioral)

Group 2

Other

No intake reminders followed by crossover to intake reminders

干预措施: Pillbox use and counselling (Behavioral)

结局指标

主要结局

Change of non-optimal timing adherence to DOACs

时间窗: 0 - 3 months, 3 - 6 months, 6 - 9 months

Non-optimal timing adherence is defined as at least one DOAC dose not recorded or recorded outside of 25% of the prescribed dosing time schedule

次要结局

  • Self-reported adherence to DOACs(0 - 6 months)
  • Clinical vascular events or death(up to 9 months)
  • Change of timing adherence to DOACs(0 - 3 months, 3 - 6 months, 6 - 9 months)
  • Change of non-optimal taking adherence to DOACs(0 - 3 months, 3 - 6 months, 6 - 9 months)
  • Change of taking adherence to DOACs(0 - 3 months, 3 - 6 months, 6 - 9 months)

研究者

发起方
University Hospital, Basel, Switzerland
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Electronic Monitoring and Improvement of Adherence... | 临床试验